首页> 外文学位 >Analysis of antioxidant responsive gene expression changes by thioredoxin system inhibitors and hypoxia.
【24h】

Analysis of antioxidant responsive gene expression changes by thioredoxin system inhibitors and hypoxia.

机译:硫氧还蛋白系统抑制剂和低氧对抗氧化剂响应基因表达变化的分析。

获取原文
获取原文并翻译 | 示例

摘要

Gene expression profiling measured by cDNA microarray offers a powerful tool for identifying cancer drug mechanism of action, defining drug specificity and for identifying new cancer drug targets. An anti-tumor inhibitor of the thioredoxin-1 (Trx-1) redox system, PX-12 (1-methylhydroxypropyl 2-imidazoloyl disulfide), is currently in Phase I clinical trials and was used as a model for targeted therapy to evaluate the differences between cells growing in culture and the same cells grown as xenografts in immunocompromised mice. Without drug treatment, MCF-7 breast cancer and HT-29 colon cancer cells growing as xenografts in severe combined immune deficient (scid ) mice showed marked changes in gene expression compared to the cells in culture, with 42% of genes showing more than a two fold difference in expression. Following treatment with PX-12, the gene changes observed in common accounted for approximately 1% of the total genes changed vivo. After elimination of the effects of Trx-1 inhibitors on known targets in vivo and in vitro, the common increase in genes involved in antioxidant response pathway was chosen for further investigation. Gene expression changes observed during microarray experimentation were validated by real-time RT-PCR. Binding and activation of Nrf2 (nuclear factor (erythroid-derived 2)-like 2) to the antioxidant responsive element (ARE) was evaluated and found to be increased by treatment with Trx-1 inhibitors and hypoxia. Potential mechanisms accounting for the increase of ARE-dependent genes, including activation of protein kinase C, PI3K (phosphoinositide-3-kinase) and p-PERK (phospho-PRKR-like endoplasmic reticulum kinase) and an increase in cellular reactive oxygen species (ROS), determined that the increase in ROS due to hypoxia and Trx-1 system inhibition was sufficient to activate the pathway. Decreasing ROS by addition of an antioxidant was able to reverse the effect of activation of this pathway. The increased expression of ARE/Nrf2 dependent genes by these mechanisms may have important implications for chemotherapy and chemoprevention of human tumors.
机译:通过cDNA微阵列测量的基因表达谱为鉴定癌症药物的作用机理,定义药物特异性和鉴定新的癌症药物靶标提供了强大的工具。硫氧还蛋白1(Trx-1)氧化还原系统的抗肿瘤抑制剂PX-12(1-甲基羟丙基2-咪唑基二硫化物)目前处于I期临床试验中,并被用作靶向治疗的模型来评估在免疫受损的小鼠中,培养的细胞与异种移植相同的细胞之间的差异。如果不进行药物治疗,则在严重的联合免疫缺陷(scid)小鼠中,异种移植生长的MCF-7乳腺癌和HT-29结肠癌细胞与培养的细胞相比,其基因表达发生了显着变化,其中42%的基因表达超过在表达上有两倍的差异。用PX-12处理后,共同观察到的基因变化约占体内体内基因总数的1%。在体内和体外消除Trx-1抑制剂对已知靶标的影响后,选择参与抗氧化反应途径的基因的共同增加进行进一步研究。通过实时RT-PCR验证了在微阵列实验期间观察到的基因表达变化。 Nrf2(核因子(类胡萝卜素衍生的2)样2)与抗氧化剂反应元件(ARE)的结合和活化得到评估,发现通过Trx-1抑制剂和低氧治疗可增加Nrf2的结合和活化。解释ARE依赖基因增加的潜在机制,包括蛋白激酶C,PI3K(磷酸肌醇-3-激酶)和p-PERK(磷酸-PRKR样内质网激酶)的激活以及细胞活性氧的增加( ROS),确定由于缺氧和Trx-1系统抑制引起的ROS的增加足以激活该途径。通过添加抗氧化剂来降低ROS能够逆转该途径的激活作用。通过这些机制增加的ARE / Nrf2依赖性基因的表达可能对人肿瘤的化学疗法和化学预防具有重要意义。

著录项

  • 作者

    Coon, Amy Elizabeth.;

  • 作者单位

    The University of Arizona.;

  • 授予单位 The University of Arizona.;
  • 学科 Biology Molecular.; Biology Cell.; Health Sciences Oncology.
  • 学位 Ph.D.
  • 年度 2006
  • 页码 120 p.
  • 总页数 120
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 分子遗传学;细胞生物学;肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号